Penn Vet doctors receive NIH grant to target canine autoimmune diseaseOctober 4, 2018Nicola J. Mason, BVetMed, PhD, and Aimee S. Payne, MD, PhD, have received the National Institutes of Health (NIH) Director's Transformative Research Award, part of the institute's High-Risk, High-Reward Research program, for their work in targeting autoimmune disease in dogs. Under the grant, Drs. Mason and Payne are looking to evaluate a genetically engineered cell-based therapy to treat dogs with naturally occurring autoimmune skin disease known as pemphigus. Dogs are one of the few other species to develop pemphigus, a condition that mirrors pemphigus in human patients. Evaluation of this approach to treat pet dogs with the disease may ultimately lead to breakthrough therapies for humans. According to the Autoimmune Disease Research Center at Johns Hopkins, at least 10 million Americans suffer from the more than 80 illnesses caused by autoimmunity. "The successful treatment of autoimmunity in the family dog using this unique approach would not only be a breakthrough in veterinary medicine, but could also change the way autoimmune disease is treated in humans," said Mason, associate professor of medicine and pathobiology at the School of Veterinary Medicine at Penn Vet. "We believe that this work may facilitate the translation of cellular immunotherapies for a broad range of canine …
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More
FDA approves Boehringer Ingelheim's Semintra for feline hypertensionOctober 2, 2018The U.S. Food & Drug Administration has approved Semintra (telmisartan oral solution) 10 mg/mL oral solution for the control of systemic hypertension in cats, according to Boehringer Ingelheim. The product was designed specifically with cats in mind to provide safe, reliable, and convenient long-term control of blood pressure, said Boehringer Ingelheim. "We are proud to continue to set new standards of care for cats to optimize their health and well-being through the veterinarian," said Shawn Hooker, global head of Strategic Business Unit Pet Vet at Boehringer Ingelheim. "Early disease detection and early treatment are key to ensure cats live longer and happier lives. With Semintra, we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension, while providing reliable long-term blood pressure control." Semintra is for oral use in cats only. The most common side effects reported in field studies include vomiting, diarrhea, lethargy, anemia, dehydration, poor appetite, and weight loss. It has not been evaluated in cats with systolic blood pressure > 200 mmHg, cats with hepatic disease, cats younger than 9 months of age, or cats that are pregnant, lactating, or intended for breeding. Visit semintra.com for …
WSAVA provides continuing education in Latin AmericaSeptember 11, 2018The World Small Animal Veterinary Association Vaccination Guidelines Group (VGG) held a series of meetings and continuing education sessions in Mexico as part of a first step in WSAVA's three-year project aimed at enhancing levels of understanding of infectious diseases among veterinarians across Latin America. WSAVA committee members, including Michael Day, VGG chairman, emeritus professor, met with veterinary association leaders, academics, first-opinion practitioners, and government regulators in Mexico City, Guadalajara, and Monterrey. They delivered three evening CE sessions and live-streamed the Mexico City session to share with registrants for 30 days after the presentation. Prior to the visit, the VGG conducted an online questionnaire to collect data on veterinary demographics, infectious disease occurrence, and vaccination protocols, and presented the results during the CE events. "Mexican veterinarians are accustomed to the principle of annual revaccination of dogs and cats with multicomponent products, but those we spoke to were excited by the new concepts of less frequent and individualized vaccination, incorporated into a preventive healthcare package for pets," said Day. "Vaccine-preventable infectious diseases such as canine distemper and parvovirus infections, remain highly prevalent in Mexico. Increasing herd immunity by improving vaccination coverage is clearly an important goal for …
AAEP announces 2018 convention keynote speakerSeptember 10, 2018Abraham Verghese, MD, educator and best-selling author, will share his keynote lecture, "A Doctor's Touch," at the American Association of Equine Practitioners' (AAEP) 2018 Convention in San Francisco. In his presentation, scheduled for Sunday, Dec. 2, Dr. Verghese will align equine medicine with human medicine and explain his vision of humanistic medicine—care-grounded medicine and the sanctity of the doctor-patient relationship. Verghese is the Linda R. Meier and Joan F. Lane Provostial Professor and Vice Chair for the Theory and Practice of Medicine at the Stanford University School of Medicine as well as a critically acclaimed author whose memoirs and novels have sold millions of copies, topped best-seller lists, and earned movie deals. In 2015, he received the National Humanities Medal from former U.S. president Barack Obama, "for reminding us that the patient is the center of the medical enterprise." To view the educational program and register for the AAEP's 64th Annual Convention, visit convention.aaep.org. The AAEP keynote address is sponsored by Merck Animal Health.
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy treatment in 18 dogs. Those that received the vaccine lived more than twice as long as the historical, matched control group, with median survival times of 956 days compared to 423 days. The expanded clinical trial is designed to collect additional safety data for the vaccine in dogs that have undergone amputation of the affected limb and have already completed chemotherapy. If the treatment is found to be as safe and effective as it appeared in the initial clinical trial, Aratana will be given full licensure, allowing it to make the drug commercially available. Live Listeria Vector (AT-014) is created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells. It is designed to supplement standard osteosarcoma treatment of amputation …
Torigen Pharma wins 2018 KC Animal Health Corridor Innovation AwardAugust 30, 2018Torigen Pharmaceuticals Inc., a Farmington, Conn., company that provides personalized cancer immunotherapies to the veterinary market, has won the Innovation Award at the KC Animal Health Corridor Investment Forum in Kansas City, Mo. Torigen presented its autologous immunotherapeutic cancer vaccine, VVax-001, for dogs during the forum. The company was honored with the award and a check for $10,000. Torigen was among 12 emerging animal health companies from three countries who competed for investments in a "Shark Tank" format with more than 400 venture capital funds, investment firms, and potential partners at the 10th annual KC Animal Health Investment Forum on Aug. 21. Each company was given 10 minutes to present their ideas followed by a five-minute Q&A. Presenting companies were seeking anywhere from $500,000 to $20 million in funding and had revenue projections of $20 million within five to seven years. A national committee of agricultural and animal health experts selected the finalists. The Investment Forum in Kansas City is one of the world's only opportunities for early-and mid-stage animal health entrepreneurs to present their business plans and provide an inside look at the newest technology and innovations to potential investors. "The Global Animal Health Investment Forum is the …
New research for canine, human Type 1 diabetes holds promiseAugust 24, 2018Reversing Type 1 diabetes in dogs and humans without the use of daily insulin injections or pumps may become a reality, thanks to a collaboration between Purdue University and the Indiana University School of Medicine. In a preclinical study, researchers developed a mixture of collagen and pancreatic cells and engineered a delivery method that successfully reversed Type 1 diabetes within 24 hours and maintained insulin independence for 90 days. A clinical study in dogs with naturally occurring Type 1 diabetes in collaboration with Purdue's College of Veterinary Medicine is next. "We plan to account for differences from mouse to human by helping dogs first," said Clarissa Hernandez Stephens, first author on the work and a graduate researcher at Purdue's Weldon School of Biomedical Engineering. "This way, the dogs can inform us on how well the treatment might work in humans." Because diabetes in dogs and humans occurs the same, both potentially could benefit from the same cure: A new set of pancreatic cells to replace islets (clusters of cells) that aren't releasing insulin to monitor blood glucose levels. Islet transplantation isn't new, and it poses challenges: It requires multiple donors, it's invasive, and large numbers of transplanted …
Blue Buffalo Clinical Trials Office celebrates second year of OSU partnershipJune 27, 2018The Blue Buffalo Veterinary Clinical Trials Office (BBVCTO) at The Ohio State University College of Veterinary Medicine is celebrating its second year supporting studies to improve the animal and human health. In the past year, the BBVCTO assisted with the design and management of more than 30 clinical trials, enabling 300 client-owned pets to participate in studies that aim to extend the lives of dogs and cats through advanced treatments. "Our partnership with Blue Buffalo has made it possible for us to provide support for studies that test new diagnostic tests and treatments across a wide spectrum of pet health including cancer, renal failure, heart disease, and arthritis," said Cheryl London, DVM, Ph.D., director of the BBVCTO and professor of veterinary biosciences. "Clinical trials in veterinary medicine are critical for identifying new approaches to more effectively detect and treat diseases in the pets we love. They also have the added benefit of advancing outcomes for people with similar diseases." Providing hope to pet parents The BBVCTO supervises clinical trials involving client-owned dogs and cats. The pets continue to live with their families during these studies with the ultimate goal of finding new therapies, diagnostic tests, and medical devices that …
Is tramadol an effective analgesic for dogs and cats?June 26, 2018Awareness of the importance of analgesia for veterinary patients has increased significantly over the past two decades. It is widely considered important, for medical and ethical reasons, to provide effective pain relief for dogs and cats, whether their pain is due to surgery, injury, or chronic medical conditions.
Why annual screening for exposure to infected ticks is vitalJune 20, 2018It's important to remember that a single tick can transmit multiple infectious agents that may cause or contribute to serious illness, including kidney disease. And because dogs don't always show clinical signs, it can be challenging to understand the true harm of any given infection to a pet's health. This makes regularly screening of pets—including asymptomatic or seemingly healthy ones—to identify exposure to infected ticks all the more important. Here's a quick look at why regular, comprehensive screening is critical, and what veterinarians can do to help keep dogs healthy. All dogs need to be screened annually for exposure to infected ticks It's quite possible a patient could be fighting an infection without showing any signs of disease. That is why limiting screening to symptomatic pets and those known to have had a tick on them is too restrictive—it will miss infections. All dogs need to be tested, and pet owners need to be reminded that negative results are the goal in order to verify that preventive measures against ticks are working. A new study reinforces the importance of detecting exposure The study, found at idexx.com/ckdstudy, showed two key findings: 1) dogs with Ehrlichia antibodies …
